We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 28, 2021

Cardiovascular Safety of Degarelix vs Leuprolide in Patients With Prostate Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Circulation 2021 Aug 30;[EPub Ahead of Print], RD Lopes, CS Higano, SF Slovin, AJ Nelson, R Bigelow, PS Sørensen, C Melloni, SG Goodman, CP Evans, J Nilsson, DL Bhatt, NW Clarke, TK Olesen, BT Doyle-Olsen, H Kristensen, L Arney, MT Roe, JH Alexander

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading